Plasma and serum brain-derived neurotrophic factor (BDNF) levels and their association with neurocognition in at-risk mental state, first episode psychosis and chronic schizophrenia patients

References

• Agnew-Blais JC, Buka SL, Fitzmaurice GM, Smoller JW, Goldstein JM, Seidman LJ. 2015. Early childhood IQ trajectories in individuals later developing schizophrenia and affective psychoses in the new england family studies. Schizophr Bull. 41:817–823.
   PubMed Web of Science ®Google Scholar
• Ahmed AO, Mantini AM, Fridberg DJ, Buckley PF. 2015. Brain-derived neurotrophic factor (BDNF) and neurocognitive deficits in people with schizophrenia: a meta-analysis. Psychiatry Res. 226:1–13.
   PubMed Web of Science ®Google Scholar
• Asevedo E, Gadelha A, Noto C, Mansur RB, Zugman A, Belangero SI, Berberian AA, Scarpato BS, Leclerc E, Teixeira AL, et al. 2013. Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia. J Psychiatr Res. 47:1376–1382.
   PubMed Web of Science ®Google Scholar
• Begliuomini S, Casarosa E, Pluchino N, Lenzi E, Centofanti M, Freschi L, Pieri M, Genazzani AD, Luisi S, Genazzani AR. 2007. Influence of endogenous and exogenous sex hormones on plasma brain-derived neurotrophic factor. Hum Reprod. 22:995–1002.
   PubMed Web of Science ®Google Scholar
• Bekinschtein P, Cammarota M, Katche C, Slipczuk L, Rossato JI, Goldin A, Izquierdo I, Medina JH. 2008. BDNF is essential to promote persistence of long-term memory storage. Proc Natl Acad Sci USA. 105:2711–2716.
   PubMed Web of Science ®Google Scholar
• Bhang SY, Choi SW, Ahn JH. 2010. Changes in plasma brain-derived neurotrophic factor levels in smokers after smoking cessation. Neurosci Lett. 468:7–11.
   PubMed Web of Science ®Google Scholar
• Bora E, Lin A, Wood SJ, Yung AR, McGorry PD, Pantelis C. 2014. Cognitive deficits in youth with familial and clinical high risk to psychosis: a systematic review and meta-analysis. Acta Psychiatr Scand. 130:1–15.
   PubMed Web of Science ®Google Scholar
• Bora E, Murray RM. 2014. Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis?. Schizophr Bull. 40:744–755.
   PubMed Web of Science ®Google Scholar
• Bora E, Yalincetin B, Akdede BB, Alptekin K. 2017. Duration of untreated psychosis and neurocognition in first-episode psychosis: a meta-analysis. Schizophr Res. 193:3–10.
   PubMed Web of Science ®Google Scholar
• Bozikas VP, Andreou C. 2011. Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature. Aust NZ J Psychiatry. 45:93–108.
   PubMed Web of Science ®Google Scholar
• Buckley PF, Pillai A, Evans D, Stirewalt E, Mahadik S. 2007. Brain derived neurotropic factor in first-episode psychosis. Schizophr Res. 91:1–5.
   PubMed Web of Science ®Google Scholar
• Buckley PF, Pillai A, Howell KR. 2011. Brain-derived neurotrophic factor: findings in schizophrenia. Curr Opin Psychiatry. 24:122–127.
   PubMed Web of Science ®Google Scholar
• Carlino D, De Vanna M, Tongiorgi E. 2013. Is altered BDNF biosynthesis a general feature in patients with cognitive dysfunctions? Neuroscientist. 19:345–353.
   PubMed Web of Science ®Google Scholar
• Carlino D, Leone E, Di Cola F, Baj G, Marin R, Dinelli G, Tongiorgi E, De Vanna M. 2011. Low serum truncated-BDNF isoform correlates with higher cognitive impairment in schizophrenia. J Psychiatr Res. 45:273–279.
   PubMed Web of Science ®Google Scholar
• Cattaneo A, Cattane N, Begni V, Pariante CM, Riva MA. 2016. The human BDNF gene: peripheral gene expression and protein levels as biomarkers for psychiatric disorders. Transl Psychiatry. 6:e958.
   PubMed Web of Science ®Google Scholar
• Conner JM, Lauterborn JC, Yan Q, Gall CM, Varon S. 1997. Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. J Neurosci. 17:2295–2313.
   PubMed Web of Science ®Google Scholar
• D’Souza DC, Pittman B, Perry E, Simen A. 2009. Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. Psychopharmacology (Berl). 202:569–578.
   PubMed Web of Science ®Google Scholar
• Delis DC, Kramer JH, Kaplan E, Ober BA. 1987. California verbal learning test (CVLT). San Antonio (TX): Psychological Corporation.
   Google Scholar
• Dinoff A, Herrmann N, Swardfager W, Lanctot KL. 2017. The effect of acute exercise on blood concentrations of brain-derived neurotrophic factor in healthy adults: a meta-analysis. Eur J Neurosci. 46:1635–1646.
   PubMed Web of Science ®Google Scholar
• Durany N, Michel T, Zochling R, Boissl KW, Cruz-Sanchez FF, Riederer P, Thome J. 2001. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res. 52:79–86.
   PubMed Web of Science ®Google Scholar
• Elfving B, Plougmann PH, Muller HK, Mathe AA, Rosenberg R, Wegener G. 2010. Inverse correlation of brain and blood BDNF levels in a genetic rat model of depression. Int J Neuropsychopharmacol. 13:563–572.
   PubMed Web of Science ®Google Scholar
• Fernandes BS, Steiner J, Berk M, Molendijk ML, Gonzalez-Pinto A, Turck CW, Nardin P, Goncalves CA. 2014. Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. Mol Psychiatry. 20:1108–1119.
   PubMed Web of Science ®Google Scholar
• Fisher M, Mellon SH, Wolkowitz O, Vinogradov S. 2016. Neuroscience-informed auditory training in schizophrenia: a final report of the effects on cognition and serum brain-derived neurotrophic factor. Schizophr Res Cogn. 3:1–7.
   PubMedGoogle Scholar
• Fusar-Poli P, Deste G, Smieskova R, Barlati S, Yung AR, Howes O, Stieglitz RD, Vita A, McGuire P, Borgwardt S. 2012. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry. 69:562–571.
   PubMed Web of Science ®Google Scholar
• Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. 2010. International consensus study of antipsychotic dosing. Am J Psychiatry. 167:686–693.
   PubMed Web of Science ®Google Scholar
• Gedika G, Schöttke H. 2001. Der Turm von Hanoi – TvH. Hogrefe Testsystem (HTS). Göttingen: Hogrefe.
   Google Scholar
• Giese M, Unternaehrer E, Brand S, Calabrese P, Holsboer-Trachsler E, Eckert A. 2013. The interplay of stress and sleep impacts BDNF level. PLoS One. 8:e76050.
   PubMed Web of Science ®Google Scholar
• Goto N, Yoshimura R, Kakeda S, Moriya J, Hayashi K, Ikenouchi-Sugita A, Umene-Nakano W, Hori H, Ueda N, Korogi Y, et al. 2009. Associations between plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early-stage schizophrenia. Hum Psychopharmacol. 24:639–645.
   PubMed Web of Science ®Google Scholar
• Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ. 2011. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry. 16:960–972.
   PubMed Web of Science ®Google Scholar
• Guzman-Marin R, Ying Z, Suntsova N, Methippara M, Bashir T, Szymusiak R, Gomez-Pinilla F, McGinty D. 2006. Suppression of hippocampal plasticity-related gene expression by sleep deprivation in rats. J Physiol. 575:807–819.
   PubMed Web of Science ®Google Scholar
• Hauser M, Zhang JP, Sheridan EM, Burdick KE, Mogil R, Kane JM, Auther A, Carrion RE, Cornblatt BA, Correll CU. 2017. Neuropsychological test performance to enhance identification of subjects at clinical high risk for psychosis and to be most promising for predictive algorithms for conversion to psychosis: a meta-analysis. J Clin Psychiatry. 78:e28–e40.
   PubMed Web of Science ®Google Scholar
• Hori H, Yoshimura R, Katsuki A, Atake K, Igata R, Konishi Y, Beppu H, Tominaga H. 2017. Blood biomarkers predict the cognitive effects of aripiprazole in patients with acute schizophrenia. Int J Mol Sci. 18:E568.
   PubMed Web of Science ®Google Scholar
• Hori H, Yoshimura R, Katsuki A, Atake K, Igata R, Konishi Y, Nakamura J. 2016. Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical antipsychotic monotherapy. World J Biol Psychiatry. 18:401–408.
   PubMed Web of Science ®Google Scholar
• Horn W. 1983. Leistungsprüfsystem (LPS). Vol. 2. Göttingen, Toronto, Zürich: Verlag für Psychologie.
   Google Scholar
• Irani F, Kalkstein S, Moberg EA, Moberg PJ. 2011. Neuropsychological performance in older patients with schizophrenia: a meta-analysis of cross-sectional and longitudinal studies. Schizophr Bull. 37:1318–1326.
   PubMed Web of Science ®Google Scholar
• Karege F, Schwald M, Cisse M. 2002. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett. 328:261–264.
   PubMed Web of Science ®Google Scholar
• Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, Knudsen GM, Aznar S. 2011. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol. 14:347–353.
   PubMed Web of Science ®Google Scholar
• Kuipers SD, Bramham CR. 2006. Brain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: new insights and implications for therapy. Curr Opin Drug Discov Devel. 9:580–586.
   PubMedGoogle Scholar
• Lehrl S. 1977. MWT-B Mehrfachwahl-Wortschatz-Test Form B. Mehrfachwahl Wortschatz Intelligenztest. MWT.B., Straube.
   Google Scholar
• Leucht S, Samara M, Heres S, Patel MX, Woods SW, Davis JM. 2014. Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull. 40:314–326.
   PubMed Web of Science ®Google Scholar
• Lukoff D, Nuechterlein KH, Ventura J. 1986. Symptom monitoring in the rehabilitation of schizophrenic patients – Appendix A. Manual for the Expanded Brief Psychiatric Rating Scale. Schizophr Bull. 12:578–603.
   PubMed Web of Science ®Google Scholar
• Man L, Lv X, Du XD, Yin G, Zhu X, Zhang Y, Soares JC, Yang XN, Chen X, Zhang XY. 2018. Cognitive impairments and low BDNF serum levels in first-episode drug-naive patients with schizophrenia. Psychiatry Res. 263:1–6.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Iorio G, Marini S, Ricci V, De Berardis D, Di Giannantonio M. 2012. Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: a review. J Biol Regul Homeost Agents. 26:347–356.
   PubMed Web of Science ®Google Scholar
• Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BW, Elzinga BM. 2014. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N = 9484). Mol Psychiatry. 19:791–800.
   PubMed Web of Science ®Google Scholar
• Mollon J, Reichenberg A. 2017. Cognitive development prior to onset of psychosis. Psychol Med. 48:1–12.
   PubMed Web of Science ®Google Scholar
• Niitsu T, Ishima T, Yoshida T, Hashimoto T, Matsuzawa D, Shirayama Y, Nakazato M, Shimizu E, Hashimoto K, Iyo M. 2014. A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia. Psychiatry Res. 215:268–273.
   PubMed Web of Science ®Google Scholar
• Niitsu T, Shirayama Y, Matsuzawa D, Hasegawa T, Kanahara N, Hashimoto T, Shiraishi T, Shiina A, Fukami G, Fujisaki M, et al. 2011. Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 35:1836–1840.
   PubMed Web of Science ®Google Scholar
• Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. 1998. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37:1553–1561.
   PubMed Web of Science ®Google Scholar
• Pillai A, Bruno D, Sarreal AS, Hernando RT, Saint-Louis LA, Nierenberg J, Ginsberg SD, Pomara N, Mehta PD, Zetterberg H, et al. 2012. Plasma BDNF levels vary in relation to body weight in females. PLoS One. 7:e39358.
   PubMed Web of Science ®Google Scholar
• Pillai A, Kale A, Joshi S, Naphade N, Raju MS, Nasrallah H, Mahadik SP. 2010. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int J Neuropsychopharmacol. 13:535–539.
   PubMed Web of Science ®Google Scholar
• Polyakova M, Stuke K, Schuemberg K, Mueller K, Schoenknecht P, Schroeter ML. 2015. BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis. J Affect Disord. 174:432–440.
   PubMed Web of Science ®Google Scholar
• Rapp C, Studerus E, Bugra H, Aston J, Tamagni C, Walter A, Pflueger M, Borgwardt S, Riecher-Rössler A. 2013. Duration of untreated psychosis and cognitive functioning. Schizophr Res. 145:43–49.
   PubMed Web of Science ®Google Scholar
• Riecher-Rössler A, Aston J, Ventura J, Merlo M, Borgwardt S, Gschwandtner U, Stieglitz RD. 2008. Basel Screening Instrument for Psychosis (BSIP): development, structure, reliability and validity. Fortschr Neurol Psychiatr. 76:207–216.
   PubMed Web of Science ®Google Scholar
• Riecher-Rössler A, Gschwandtner U, Aston J, Borgwardt S, Drewe M, Fuhr P, Pflüger M, Radü W, Schindler C, Stieglitz RD. 2007. The Basel early-detection-of-psychosis (FePsy)-study - design and preliminary results. Acta Psychiatr Scand. 115:114–125.
   PubMed Web of Science ®Google Scholar
• Riecher-Rössler A, Pflueger MO, Aston J, Borgwardt SJ, Brewer WJ, Gschwandtner U, Stieglitz RD. 2009. Efficacy of using cognitive status in predicting psychosis: a 7-year follow-up. Biol Psychiatry. 66:1023–1030.
   PubMed Web of Science ®Google Scholar
• Riecher-Rössler A, Studerus E. 2017. Prediction of conversion to psychosis in individuals with an at-risk mental state. A brief update on recent developments. Curr Opin Psychiatry. 30:209–219.
   PubMed Web of Science ®Google Scholar
• Rosvold HE, Mirsky AF, Sarason I, Bransome EDJ, Beck LH. 1956. A continuous performance test of brain damage. J Cons Psychol. 20:343–350.
   Google Scholar
• Ruiz de Azua S, Matute C, Stertz L, Mosquera F, Palomino A, de la Rosa I, Barbeito S, Vega P, Kapczinski F, Gonzalez-Pinto A. 2013. Plasma brain-derived neurotrophic factor levels, learning capacity and cognition in patients with first episode psychosis. BMC Psychiatry. 13:27.
   PubMed Web of Science ®Google Scholar
• Sartorius A, Hellweg R, Litzke J, Vogt M, Dormann C, Vollmayr B, Danker-Hopfe H, Gass P. 2009. Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry. 42:270–276.
   PubMed Web of Science ®Google Scholar
• Studerus E, Riecher-Rössler A, Papmeyer M. 2016. Neurocognition and motor functioning in the prediction of psychosis. In: Riecher-Rössler AMP, editor. Early detection and intervention in psychosis. Basel: Karger; p. 116–132.
   Google Scholar
• Sun ZL, Liu J, Guo W, Jiang T, Ma C, Li WB, Tang YL, Ling SH. 2016. Serum brain-derived neurotrophic factor levels associate with cognitive improvement in patients with schizophrenia treated with electroacupuncture. Psychiatry Res. 244:370–375.
   PubMed Web of Science ®Google Scholar
• Szoke A, Trandafir A, Dupont ME, Meary A, Schurhoff F, Leboyer M. 2008. Longitudinal studies of cognition in schizophrenia: meta-analysis. Br J Psychiatry. 192:248–257.
   PubMed Web of Science ®Google Scholar
• Theleritis C, Fisher HL, Shafer I, Winters L, Stahl D, Morgan C, Dazzan P, Breedvelt J, Sambath I, Vitoratou S, et al. 2014. Brain derived neurotropic factor (BDNF) is associated with childhood abuse but not cognitive domains in first episode psychosis. Schizophr Res. 159:56–61.
   PubMed Web of Science ®Google Scholar
• Toll A, Mane A. 2015. Brain-derived neurotrophic factor levels in first episode of psychosis: a systematic review. World J Psychiatry. 5:154–159.
   PubMed Web of Science ®Google Scholar
• Tsuchimine S, Sugawara N, Ishioka M, Yasui-Furukori N. 2014. Preanalysis storage conditions influence the measurement of brain-derived neurotrophic factor levels in peripheral blood. Neuropsychobiology. 69:83–88.
   PubMed Web of Science ®Google Scholar
• Ventura J, Lukoff D, Nuechterlein KH, Liberman RP, Green MJ, Shaner A. 1993. Training and quality assurance with the brief psychiatric rating scale: “The Drift Busters” – Appendix 1. The Brief Psychiatric Rating Scale (expanded version). Int J Meth Psychiatric Res. 3:221–224.
   Web of Science ®Google Scholar
• Vinogradov S, Fisher M, Holland C, Shelly W, Wolkowitz O, Mellon SH. 2009. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia?. Biol Psychiatry. 66:549–553.
   PubMed Web of Science ®Google Scholar
• Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE. 2003. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry. 8:592–610.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). 1994. Internationale Klassifikation psychischer Störungen: ICD-10, Kapitel V (F); Forschungskriterien. Huber.
   Google Scholar
• Xiao W, Ye F, Liu C, Tang X, Li J, Dong H, Sha W, Zhang X. 2017. Cognitive impairment in first-episode drug-naive patients with schizophrenia: relationships with serum concentrations of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. Prog Neuropsychopharmacol Biol Psychiatry. 76:163–168.
   PubMed Web of Science ®Google Scholar
• Yamada K, Nabeshima T. 2003. Brain-derived neurotrophic factor/TrkB signaling in memory processes. J Pharmacol Sci. 91:267–270.
   PubMed Web of Science ®Google Scholar
• Yung AR, Phillips LJ, McGorry PD, McFarlane CA, Francey S, Harrigan S, Patton GC, Jackson HJ. 1998. Prediction of psychosis. A step towards indicated prevention of schizophrenia. Br J Psychiatry Suppl. 172:14–20.
   PubMedGoogle Scholar
• Zhang XY, Chen DC, Xiu MH, Haile CN, Luo X, Xu K, Zhang HP, Zuo L, Zhang Z, Zhang X, et al. 2012. Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls. Hum Genet. 131:1187–1195.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Liang J, Chen DC, Xiu MH, Yang FD, Kosten TA, Kosten TR. 2012. Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia. Psychopharmacology (Berl). 222:277–284.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Xiu MH, Chen DC, Yang FD, Wu GY, Lu L, Kosten TA, Kosten TR. 2010. Nicotine dependence and serum BDNF levels in male patients with schizophrenia. Psychopharmacology (Berl). 212:301–307.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Fang X, Fan W, Tang W, Cai J, Song L, Zhang C. 2018. Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study. Psychopharmacology (Berl). 235:1191–1198.
   PubMed Web of Science ®Google Scholar
• Zimmermann P, Fimm B. 2002. A test battery for attentional performance. In: Leclercq M, Zimmermann P, editors. Applied neuropsychology of attention: theory, diagnosis and rehabilitation. Psychology Press; p. 110–151.
   Google Scholar